- Home
- BSLK vs MRNS Comparison
BSLK vs MRNS Comparison
Compare BSLK & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- MRNS
- Stock Information
- Founded
- BSLK 2009
- MRNS 2003
- Country
- BSLK United States
- MRNS United States
- Employees
- BSLK N/A
- MRNS N/A
- Industry
- BSLK
- MRNS Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- MRNS Health Care
- Exchange
- BSLK NYSE
- MRNS Nasdaq
- Market Cap
- BSLK 16.0M
- MRNS 15.1M
- IPO Year
- BSLK N/A
- MRNS 2014
- Fundamental
- Price
- BSLK $0.36
- MRNS $0.24
- Analyst Decision
- BSLK
- MRNS Buy
- Analyst Count
- BSLK 0
- MRNS 12
- Target Price
- BSLK N/A
- MRNS $4.28
- AVG Volume (30 Days)
- BSLK 4.5M
- MRNS 830.0K
- Earning Date
- BSLK 11-07-2024
- MRNS 11-12-2024
- Dividend Yield
- BSLK N/A
- MRNS N/A
- EPS Growth
- BSLK N/A
- MRNS N/A
- EPS
- BSLK N/A
- MRNS N/A
- Revenue
- BSLK $1,489,000.00
- MRNS $31,466,000.00
- Revenue This Year
- BSLK N/A
- MRNS $15.71
- Revenue Next Year
- BSLK N/A
- MRNS $40.57
- P/E Ratio
- BSLK $0.08
- MRNS N/A
- Revenue Growth
- BSLK N/A
- MRNS 1.63
- 52 Week Low
- BSLK $0.23
- MRNS $0.23
- 52 Week High
- BSLK $17.02
- MRNS $11.26
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- MRNS 25.86
- Support Level
- BSLK N/A
- MRNS $0.23
- Resistance Level
- BSLK N/A
- MRNS $0.30
- Average True Range (ATR)
- BSLK 0.00
- MRNS 0.02
- MACD
- BSLK 0.00
- MRNS 0.02
- Stochastic Oscillator
- BSLK 0.00
- MRNS 12.59
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc formerly Golden Arrow Merger Corp is an shell company.
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.